PRB1 and dermatomyositis: In a study performed on a multicenter international cohort of SSc patients, anti-PM/Scl+ subjects were clinically characterized by a higher incidence of myositis, ILD (with a good functional outcome in the first decade of the disease), calcinosis, cutaneous signs of dermatomyositis, and pulmonary fibrosis [2,43,44].